drugset / Trial / NCT00827190

Study Evaluating Single Ascending Doses Of ILS-920

NCT00827190 ↗

Phase 1 Completed 16 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single intravenous (IV) doses to healthy adult subjects.

Timeline

Start
2009-02
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ILS-920 Small molecule — Intravenous

Indications